What is Generate Biomedicines, Inc. 's free cash flow?

Generate Biomedicines, Inc. (GENB) reported free cash flow of -$84.17M in Q1 2026.

What does free cash flow mean?

Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Generate Biomedicines, Inc. GENB Free cash flow

Free cash flow at other companies

MYR GroupMYRG

$68.62M-2.3%

SSR MiningSSRM

$175.66M+368%

Piper SandlerPIPR

-$293.87M-34.6%

RepligenRGEN

$23.59M+106%

LKQLKQ

-$96M-68.4%

Sensata TechnologiesST

$104.6M+20.8%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Calculated from Generate Biomedicines, Inc. ’s reported figures.

−$80.4Mnet cash from operating−$3.8Mcapital expenditures=-$84.17M

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's free cash flow?: Generate Biomedicines, Inc. (GENB) reported free cash flow of -$84.17M in Q1 2026.
What does free cash flow mean?: Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.